Spinogenix adds Phase IIb autism study to CLARITY basket trial

Spinogenix has broadened its ongoing Phase IIb/III CLARITY basket trial to include a Phase IIb study of codabakalner in idiopathic ASD. The trial marks Spinogenix’s first study in autism, assessing the oral compound’s effects on sensory, emotional and cognitive symptoms. Patients with idiopathic ASD will be screened via EEG and enrolled if they exhibit heightened resting gamma band power. Credit: Berit Kessler/Shutterstock.com. Spinogenix has broadened its ongoing Phase IIb/III CLARITY basket trial to include a Phase IIb study of codabakalner (SPG601) in idiopathic autism spectrum disorder (ASD). The trial marks the biopharmaceutical firm’s first study in autism, assessing the oral…

Source: Clinical Trials Arena